News|Articles|December 29, 2025

Top 5 type 1 diabetes news articles of 2025

Listen

0:00 / 0:00

Key Takeaways

COUR Pharmaceuticals is exploring nanoparticle therapy to prevent islet cell destruction and trigger a T cell response in type 1 diabetes.
NIH funding cuts could significantly impact type 1 diabetes research, as highlighted by Aaron J. Kowalski, Ph.D.
The American Diabetes Association's updated guidelines emphasize antibody-based screening and Tzield discussions for type 1 diabetes management.
Sana Biotechnology's hypoimmune platform offers potential in making genetically modified cells invisible to the immune system.
Vertex's Zimislecel, an allogeneic stem cell-derived islet cell therapy, is in phase 3 trials and may eliminate the need for insulin.

This year in type 1 diabetes, researchers advanced immune-reprogramming nanoparticle therapies and hypoimmune stem cell transplants, launched pivotal islet cell therapy trials, updated screening and treatment guidelines, and warned that cuts to research funding could slow future innovation.

1. Nanoparticle therapy has potential to reprogram the immune system in type 1 diabetes

COUR Pharmaceuticals is about to begin a phase 1b/2a study to assess a therapy for type 1 diabetes that prevents islet cell destruction and triggers a T cell response.

2. Cuts to indirect research costs to impact type 1 diabetes

Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, spoke with Managed Healthcare Executive about the possible impacts of the NIH’s cuts to indirect research funding.

3. Diabetes Association updates guidelines for type 1 diabetes

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 diabetes and recommend that physicians discuss potential use of Tzield, a monoclonal antibody approved to delay the onset of the symptoms of the disease.

4. New type of stem cell transplant shows promise in type 1 diabetes

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.

5. Phase 3 trial of Vertex’s islet cell therapy for type 1 diabetes under way

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!